Attenuation of argininosuccinate lyase inhibits cancer growth via cyclin A2 and nitric oxide

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2505-2516

  Huang, Hau Lun ^a,b   Hsu, Hui Ping ^c   Shieh, Shu Chus ^d   Chang, Yung Sheng ^a,b   Chen, Wei Ching ^a,b   Cho, Chien Yu ^a,b   Teng, Chiao Fang ^a   Su, Ih Jen ^f   Hung, Wen Chun ^g   Lai, Ming Derg ^a,b,e  

^a Institute of Basic Medical Sciences   (Taiwan)

^b Institute of Biochemistry and Molecular Biology   (Taiwan)

^c Departments of Surgery   (Taiwan)

^d Departments of Medical Laboratory Science and Biotechnology   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f National Institute of Infectious Diseases and Vaccinology   (Taiwan)

^g NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARGININOSUCCINATE LYASE; CYCLIN A2; NITRIC OXIDE; SHORT HAIRPIN RNA;

ANIMAL CELL; ARTICLE; ATTENUATION; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL GROWTH; CELL SURVIVAL; CLINICAL ARTICLE; COLONY FORMATION; ENDOPLASMIC RETICULUM STRESS; FEEDBACK SYSTEM; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRUS INFECTION; LIVER CANCER; LIVER TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANIMALS; ARGININE; ARGININOSUCCINATE LYASE; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN A2; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NITRIC OXIDE; RNA, SMALL INTERFERING;

EID: 84887455091     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood1997;89:206778.
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
3. Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, et al. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol 2008;83:144-9.
4. Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 1995; 2:503-8.
5. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-47.
6. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274:1652-9.
7. Kisselev Alexei F, van der Linden WA, Overkleeft Herman S. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 2012;19:99-115.
8. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasomeinhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011;103:1007-17.
9. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
10. Chen ZJ. Ubiquitin signalling in the NF-[kappa]B pathway. Nat Cell Biol 2005;7:758-65.
11. Schwartz AL, Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009;49:73-96.
12. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kB activity. Annu Rev Immunol 2000;18:621-63.
13. Belardo G, Piva R, Santoro MG. Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells. Leukemia 2010;24:187-96.
14. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010;116: 1515-23.
15. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-[kappa]B as the matchmaker. Nat Immunol 2011;12:715-23.
16. Sung MH, Simon R. In silico simulation of inhibitor drug effects on nuclear factor-kappaB pathway dynamics. Mol Pharmacol 2004;66: 70-5.
17. Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, et al. Bortezomib is synergistic with rituximab and cyclophosphamide inducing apoptosisof mantle cell lymphoma cells in vitro and in vivo. Leukemia 2008;22:179-85.
18. Suh KS, Goy A. Bortezomib in mantle cell lymphoma. Future Oncol 2008;4:149-68.
19. Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle celllymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520-5.
20. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24: 4867-74.
21. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-91.
22. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-90.
23. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009;114: 3439-47.
24. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15:7085-91.
25. Sturm RA, Das G, Herr W. The ubiquitous octamer-binding protein Oct- 1 contains a POU domain with a homeo box subdomain. Genes Dev 1988;2:1582-99.
26. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, et al. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 2008;14: 2154-60.
27. Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996;184:1331-41.
28. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cellsleads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171:88-95.
29. Angeles A, Fung G, Luo H. Immune and non-immune functions of the immunoproteasome. Front Biosci 2012;17:1904-16.
30. Vigneron N, Van den Eynde BJ. Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. Curr Opin Immunol 2012;24:84-91.
31. Kuhn DJ, Orlowski RZ. The immunoproteasome as a target in hematologic malignancies. Semin Hematol 2012;49:258-62.
32. Lee W, Kim KB. The immunoproteasome: an emerging therapeutic target. Curr Top Med Chem 2011;11:2923-30.
33. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20.
34. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120: 2817-25.
35. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011;17: 2734-43.
36. Orlowski RZ. The ubiquitin proteasome pathway from bench to bedside. Hematology Am Soc Hematol Educ Program 2005; 220-5.
37. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/Sarrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005;70:700-13.
38. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NFkappa B transcription factor. Science 1988;242:540-6.
39. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009;114:1046-52.
40. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunit 1999;10:105-15.
41. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
42. Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, McDonnell TJ. Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours. J Pathol 2003;199: 84-9.
43. Yared MA, Khoury JD, Medeiros LJ, Rassidakis GZ, Lai R. Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. Arch Pathol Lab Med 2005;129:990-6.